loading
Schlusskurs vom Vortag:
$4.90
Offen:
$4.91
24-Stunden-Volumen:
204.10K
Relative Volume:
0.34
Marktkapitalisierung:
$284.92M
Einnahmen:
$192.64M
Nettoeinkommen (Verlust:
$2.51M
KGV:
18.07
EPS:
0.27
Netto-Cashflow:
$12.42M
1W Leistung:
-4.51%
1M Leistung:
+2.96%
6M Leistung:
-4.70%
1J Leistung:
+41.16%
1-Tages-Spanne:
Value
$4.83
$4.935
1-Wochen-Bereich:
Value
$4.82
$5.12
52-Wochen-Spanne:
Value
$3.44
$6.75

Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile

Name
Firmenname
Vanda Pharmaceuticals Inc
Name
Telefon
202-734-3400
Name
Adresse
2200 PENNSYLVANIA AVE NW, WASHINGTON
Name
Mitarbeiter
203
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
VNDA's Discussions on Twitter

Vergleichen Sie VNDA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
VNDA 4.88 284.92M 192.64M 2.51M 12.42M 0.27
VRTX 449.81 115.43B 10.63B -479.80M -1.35B 13.33
REGN 747.38 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 591.88 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.12 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 107.58 24.89B 3.30B -501.07M 1.03B 11.54

Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-07-11 Eingeleitet Cantor Fitzgerald Overweight
2022-02-25 Herabstufung Jefferies Buy → Hold
2021-05-12 Eingeleitet BofA Securities Buy
2021-01-14 Herabstufung Citigroup Buy → Neutral
2020-10-29 Hochstufung Citigroup Neutral → Buy
2020-06-09 Herabstufung Citigroup Buy → Neutral
2020-03-16 Herabstufung Oppenheimer Perform → Underperform
2020-03-12 Hochstufung Citigroup Neutral → Buy
2019-11-07 Herabstufung Citigroup Buy → Neutral
2019-08-01 Hochstufung Citigroup Neutral → Buy
2019-07-25 Herabstufung Stifel Buy → Hold
2018-12-11 Herabstufung Oppenheimer Outperform → Perform
2018-12-04 Hochstufung Cantor Fitzgerald Neutral → Overweight
2018-12-04 Bestätigt Jefferies Buy
2018-11-08 Fortgesetzt Jefferies Buy
2018-09-21 Fortgesetzt Oppenheimer Outperform
2018-05-23 Eingeleitet Citigroup Buy
2018-01-19 Eingeleitet Seaport Global Securities Buy
2017-09-14 Bestätigt Piper Jaffray Overweight
2017-06-27 Fortgesetzt Piper Jaffray Overweight
2017-05-26 Eingeleitet H.C. Wainwright Buy
2017-04-12 Eingeleitet Oppenheimer Outperform
2016-11-09 Eingeleitet Aegis Capital Buy
2016-10-06 Fortgesetzt Jefferies Buy
Alle ansehen

Vanda Pharmaceuticals Inc Aktie (VNDA) Neueste Nachrichten

pulisher
Nov 19, 2024

Long Term Trading Analysis for (VNDA) - Stock Traders Daily

Nov 19, 2024
pulisher
Nov 18, 2024

Vanda Pharmaceuticals director sells $25,863 in stock - Investing.com India

Nov 18, 2024
pulisher
Nov 18, 2024

Vanda Pharmaceuticals director sells $25,863 in stock By Investing.com - Investing.com UK

Nov 18, 2024
pulisher
Nov 17, 2024

Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.com - MarketBeat

Nov 17, 2024
pulisher
Nov 14, 2024

New Strong Buy Stocks For November 14th - Barchart

Nov 14, 2024
pulisher
Nov 13, 2024

Vanda Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com Nigeria

Nov 13, 2024
pulisher
Nov 12, 2024

Vanda Pharmaceuticals to Present at Major Stifel, Jefferies Healthcare Conferences | VNDA Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 12, 2024

BML Capital Management LLC Sells 169,780 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat

Nov 12, 2024
pulisher
Nov 09, 2024

Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com - MarketBeat

Nov 09, 2024
pulisher
Nov 08, 2024

Earnings call: Vanda Pharmaceuticals reports mixed Q3 2024 results - Investing.com India

Nov 08, 2024
pulisher
Nov 08, 2024

Earnings call: Vanda Pharmaceuticals reports mixed Q3 2024 results By Investing.com - Investing.com Australia

Nov 08, 2024
pulisher
Nov 08, 2024

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 08, 2024
pulisher
Nov 07, 2024

Vanda Pharmaceuticals Inc (VNDA) Quarterly 10-Q Report - Quartz

Nov 07, 2024
pulisher
Nov 07, 2024

Vanda Seeks New Markets for Hetlioz Amid Generic Competition - Sleep Review

Nov 07, 2024
pulisher
Nov 07, 2024

Vanda: Q3 Earnings Snapshot - Middletown Press

Nov 07, 2024
pulisher
Nov 07, 2024

Vanda Pharmaceuticals Inc (VNDA) Q3 2024 Earnings Call Highlights: Revenue Surge Amidst Rising ... - Yahoo Finance

Nov 07, 2024
pulisher
Nov 06, 2024

Vanda Pharmaceuticals Reports Strong Q3 2024 Growth - TipRanks

Nov 06, 2024
pulisher
Nov 06, 2024

Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results - PR Newswire

Nov 06, 2024
pulisher
Nov 05, 2024

Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve

Nov 05, 2024
pulisher
Nov 05, 2024

Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks - Simply Wall St

Nov 05, 2024
pulisher
Nov 04, 2024

Analysts Set Expectations for VNDA Q3 Earnings - MarketBeat

Nov 04, 2024
pulisher
Nov 02, 2024

Vanda started at buy by H.C. Wainwright, negative enterprise value cited - MSN

Nov 02, 2024
pulisher
Nov 01, 2024

Over 200% Stock UpsideVanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Brokers Issue Forecasts for VNDA FY2024 Earnings - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

StockNews.com Begins Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

Vanda Pharmaceuticals (VNDA) Set to Announce Quarterly Earnings on Wednesday - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Buy Rating from Analysts at HC Wainwright - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

VNDAVanda Pharmaceuticals Inc. Latest Stock News & Market Updates - StockTitan

Oct 31, 2024
pulisher
Oct 30, 2024

Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024 - StockTitan

Oct 30, 2024
pulisher
Oct 28, 2024

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Sees Significant Growth in Short Interest - MarketBeat

Oct 28, 2024
pulisher
Oct 24, 2024

Vanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated at StockNews.com - MarketBeat

Oct 24, 2024
pulisher
Oct 22, 2024

Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More - MSN

Oct 22, 2024
pulisher
Oct 21, 2024

Allergic Conjunctivitis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO - The Globe and Mail

Oct 21, 2024
pulisher
Oct 19, 2024

Vanda Pharma soars as Cycle Pharma reiterates $8/share offer (update) - MSN

Oct 19, 2024
pulisher
Oct 17, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc.VNDA - PR Newswire

Oct 17, 2024
pulisher
Oct 15, 2024

VNDA Rejects Second Takeover Bid by Cycle Group, Stock Rises - Yahoo Finance

Oct 15, 2024
pulisher
Oct 15, 2024

Cycle Pharmaceuticals Makes Bold Move To Acquire Vanda Pharma - Finimize

Oct 15, 2024
pulisher
Oct 15, 2024

Cycle Pharmaceuticals reaffirms proposal to acquire Vanda Pharmaceuticals - Yahoo Finance

Oct 15, 2024
pulisher
Oct 15, 2024

D.C. drugmaker Vanda rejects another acquisition offer - The Business Journals

Oct 15, 2024
pulisher
Oct 15, 2024

Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share - BioSpace

Oct 15, 2024
pulisher
Oct 14, 2024

Vanda Pharmaceuticals rejects Cycle Pharma's second takeover offer - Reuters

Oct 14, 2024
pulisher
Oct 14, 2024

Vanda Pharmaceuticals Rejects Deal Proposal From Cycle Group - MarketWatch

Oct 14, 2024
pulisher
Oct 14, 2024

Cycle Pharmaceuticals Stands By $488 Million Offer for Vanda - Yahoo Finance

Oct 14, 2024
pulisher
Oct 14, 2024

Vanda Pharmaceuticals rejects Cycle Group's $8.00 per share bid - Investing.com

Oct 14, 2024

Finanzdaten der Vanda Pharmaceuticals Inc-Aktie (VNDA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):